Resistance to DNA repair inhibitors in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The DNA damage response (DDR) network maintains genome integrity and prevents cancer development.
• Defects in DDR pathways are hallmarks of cancer, making DDR enzymes therapeutic targets.
• PARP inhibitors (PARPi) are clinically used for specific cancer types with DDR defects.

Purpose of the Study:

• To discuss emerging resistance mechanisms to novel DDR-targeted therapies.
• To leverage understanding of PARP inhibitor resistance to predict and counter resistance to new DDR drugs.
• To explore strategies for overcoming therapy resistance in cancer treatment.

Main Methods:

• Review of existing literature on DDR pathways and cancer therapy resistance.
• Analysis of resistance mechanisms to PARP inhibitors.
• Discussion of pre-clinical and clinical investigations of novel DDR targets (e.g., ATR, WRN, Polθ).

Main Results:

• Resistance to DDR-targeted therapies is a significant clinical challenge.
• Understanding PARPi resistance provides insights into potential resistance to other DDR inhibitors.
• Novel DDR targets like ATR, WRN, and Polθ are under investigation.

Conclusions:

• Strategies to overcome resistance are essential for the success of novel DDR-targeted cancer therapies.
• Proactive management of resistance mechanisms will improve patient outcomes.
• Further research into DDR and resistance is critical for advancing cancer treatment.